AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25050340 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg i.v. (ONS group)
Number of subjects: 64
Study 22207026 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacromial patient-controlled analgesia (SA-PCA) with 0.5% ropivacaine at a rate of 2 ml/h and a patient-controlled bolus dose of 2 ml.
Number of subjects: 60
Study 22207026 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (IV-PCA).
Number of subjects: 60
Study 22207026 — intervention group
Group type: COMPARATOR
Intervention: IV-PCA
Number of subjects: 60
Study 22207026 — intervention group
Group type: EXPERIMENTAL
Intervention: SA-PCA
Number of subjects: 60
Study 19633051 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoendocrine adjuvant therapy without goserelin in premenopausal patients with endocrine-responsive tumors
Number of subjects: 2754
Study 19633051 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin in patients with tumors showing PVI
Number of subjects: 2754
Study 19633051 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen in all patients in trial IX
Number of subjects: 2754
Study 19633051 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate endocrine adjuvant therapy
Number of subjects: 2754
Study 18922373 — intervention group
Group type: EXPERIMENTAL
Intervention: Alumina ceramic-on-alumina ceramic bearing couples
Number of subjects: 452
Study 18922373 — intervention group
Group type: COMPARATOR
Intervention: Conventional polyethylene-on-metal bearing group
Number of subjects: 452
Study 16881941 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard depression treatment plus literacy education
Number of subjects: 70
Study 16881941 — intervention group
Group type: COMPARATOR
Intervention: Standard depression treatment
Number of subjects: 70
Study 12969359 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-2 coated xenogenic bone substitute mineral
Number of subjects: 11
Study 12969359 — intervention group
Group type: COMPARATOR
Intervention: Control (xenogenic bone substitute without rhBMP-2)
Number of subjects: 11
Study 11125655 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 plaintiff
Number of subjects: 135
Study 11125655 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 plaintiffs
Number of subjects: 135
Study 11125655 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 plaintiffs
Number of subjects: 135
Study 11125655 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 plaintiffs
Number of subjects: 135
Study 11125655 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 plaintiffs
Number of subjects: 135
Study 9196416 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegic reperfusion with leucocyte depletion (n = 11)
Number of subjects: 44
Study 9196416 — intervention group
Group type: COMPARATOR
Intervention: Blood cardioplegic reperfusion without leucocyte depletion (n = 11)
Number of subjects: 44
Study 9196416 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte depleted (n = 11)
Number of subjects: 44
Study 9196416 — intervention group
Group type: COMPARATOR
Intervention: Blood cardioplegia (n = 11)
Number of subjects: 44
Study 9196416 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte depletion in patients with normal ejection fraction (n = 11)
Number of subjects: 44
Study 9196416 — intervention group
Group type: COMPARATOR
Intervention: Control group for normal ejection fraction (n = 11)
Number of subjects: 44
Study 8263575 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 395
Study 8263575 — intervention group
Group type: COMPARATOR
Intervention: Eligible Refusers (no TPN)
Number of subjects: 395
Study 8263575 — intervention group
Group type: COMPARATOR
Intervention: Index Group (no TPN)
Number of subjects: 395
Study 3884152 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/m2/day orally
Number of subjects: 13
Study 3884152 — intervention group
Group type: COMPARATOR
Intervention: 100 mg/m2/day iv
Number of subjects: 13
Study 3884152 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral VP‐16
Number of subjects: 13
Study 30232721 — intervention group
Group type: EXPERIMENTAL
Intervention: LI-ESWT
Number of subjects: 128
Study 30232721 — intervention group
Group type: EXPERIMENTAL
Intervention: PDE5i
Number of subjects: 128
Study 30232721 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 128
Study 30232721 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 128
Study 30232721 — intervention group
Group type: COMPARATOR
Intervention: LI-ESWT vs Control
Number of subjects: 128
Study 26783317 — intervention group
Group type: EXPERIMENTAL
Intervention: Lying flat 'head down' position for 48 hours
Number of subjects: 92
Study 26783317 — intervention group
Group type: COMPARATOR
Intervention: Sitting up position for 48 hours
Number of subjects: 92
Study 24392497 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic mouthwash along with oral analgesic post biopsy (Group B)
Number of subjects: 300
Study 24392497 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic mouthwash alone (Group C)
Number of subjects: 300
Study 24392497 — intervention group
Group type: COMPARATOR
Intervention: No analgesic post biopsy, except when required (Group A)
Number of subjects: 300
Study 22321518 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Home walking program
Number of subjects: 102
Study 22321518 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Group (UCG) - Control
Number of subjects: 102
Study 20188627 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivated group 1 (25 Euro cent reward)
Number of subjects: 33
Study 20188627 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivated group 2 (50 Euro cent reward)
Number of subjects: 33
Study 20188627 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reward)
Number of subjects: 33
Study 17970786 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC) with cyclophosphamide and thiotepa after six courses of cyclophosphamide, doxorubicin, and 5-fluorouracil followed by tamoxifen.
Number of subjects: 97
Study 17970786 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose (STD) chemotherapy with six courses of cyclophosphamide, doxorubicin, and 5-fluorouracil followed by tamoxifen.
Number of subjects: 97
Study 17970786 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC)
Number of subjects: 97
Study 17970786 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose (STD) chemotherapy
Number of subjects: 97
Study 15997634 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg bid (group 1)
Number of subjects: 44
Study 15997634 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg bid + nitrendipine 20 mg qd (group 2)
Number of subjects: 44
Study 15997634 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (enalapril + nitrendipine)
Number of subjects: 44
Study 15997634 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (enalapril)
Number of subjects: 44
Study 15997634 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 12808267 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (cycle ergometer training for 3 months)
Number of subjects: 28
Study 12808267 — intervention group
Group type: COMPARATOR
Intervention: Control group (inactive sedentary lifestyle)
Number of subjects: 28
Study 10581136 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent placement
Number of subjects: 143
Study 10581136 — intervention group
Group type: COMPARATOR
Intervention: PTCA alone
Number of subjects: 143
Study 10581136 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal PTCA result
Number of subjects: 143
Study 10581136 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting required
Number of subjects: 143
Study 8768019 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% hyperbaric bupivacaine
Number of subjects: 50
Study 8768019 — intervention group
Group type: COMPARATOR
Intervention: 0.5% hyperbaric bupivacaine
Number of subjects: 50
Study 2054268 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg as enteric coated granules administered alone
Number of subjects: 8
Study 2054268 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg as enteric coated granules administered after ranitidine 300 mg
Number of subjects: 8
Study 6336977 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer Factor (TF)
Number of subjects: 36
Study 6336977 — intervention group
Group type: COMPARATOR
Intervention: Control (surgery only)
Number of subjects: 36
Study 29778344 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with pharmacist intervention (medication reconciliation, medication review, participation in ward rounds)
Number of subjects: 460
Study 29778344 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with pharmacist intervention
Number of subjects: 460
Study 29778344 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 460
Study 29148019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutures group (running 4-0 absorbable subcuticular suture, 82 cases)
Number of subjects: 165
Study 29148019 — intervention group
Group type: COMPARATOR
Intervention: Staples group (interrupted suture with staples, 83 cases)
Number of subjects: 165
Study 29148019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutures group
Number of subjects: 165
Study 29148019 — intervention group
Group type: COMPARATOR
Intervention: Staples group
Number of subjects: 165
Study 29148019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutures group and Staples group
Number of subjects: 165
Study 27648957 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordered mesoporous silica formulation of fenofibrate
Number of subjects: 12
Study 27648957 — intervention group
Group type: COMPARATOR
Intervention: Marketed product based on micronized fenofibrate
Number of subjects: 12
Study 24613691 — intervention group
Group type: EXPERIMENTAL
Intervention: PVS‐10200 (low-dose cohort A)
Number of subjects: 21
Study 24613691 — intervention group
Group type: EXPERIMENTAL
Intervention: PVS‐10200 (high-dose cohort B)
Number of subjects: 21
Study 23364035 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nutritional education program (two counseling sessions and two telephone sessions over 6 weeks)
Number of subjects: 40
Study 23364035 — intervention group
Group type: COMPARATOR
Intervention: Control group (nutritional counseling after data collection)
Number of subjects: 40
Study 20399511 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy with tympanostomy (A+T)
Number of subjects: 78
Study 20399511 — intervention group
Group type: COMPARATOR
Intervention: Adenoidectomy with myringotomy (A+M)
Number of subjects: 78
Study 17389731 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum digoxin concentrations (SDC) (0.5-0.9 ng/mL)
Number of subjects: 2890
Study 17389731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2890
Study 17389731 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum digoxin concentrations (SDC) (≥ 1 ng/mL)
Number of subjects: 2890
Study 17389731 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose digoxin (≤ 0.125 mg/d)
Number of subjects: 2890
Study 15165120 — intervention group
Group type: EXPERIMENTAL
Intervention: cAMP and cGMP levels in sera and platelets
Number of subjects: 120
Study 15165120 — intervention group
Group type: EXPERIMENTAL
Intervention: cGMP levels in leucocytes
Number of subjects: 120
Study 12213693 — intervention group
Group type: EXPERIMENTAL
Intervention: PROSPECT (citalopram and/or IPT)
Number of subjects: 255
Study 12213693 — intervention group
Group type: COMPARATOR
Intervention: MTLD-2 (paroxetine and IPT)
Number of subjects: 255
Study 9690571 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 2000 microg/d
Number of subjects: 13
Study 9690571 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 microg or 1000 microg BID
Number of subjects: 13
Study 9690571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 7857343 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of pidotimod (200 mg in bolus)
Number of subjects: 60
Study 7857343 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of pidotimod at 200, 400, and 800 mg
Number of subjects: 60
Study 7857343 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of pidotimod at 50, 100, and 200 mg (12 volunteers/group) twice a day for 15 days
Number of subjects: 60
Study 7857343 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of pidotimod (800 mg) in different formulations (sachets, vials, tablets)
Number of subjects: 60
Study 2575335 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate (200 mg/day, corresponding to 30 mg zinc metal)
Number of subjects: 0
Study 2575335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31184516 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized in-hospital exercise training program
Number of subjects: 26
Study 30630742 — intervention group
Group type: EXPERIMENTAL
Intervention: LCHF diet during Adapt trial
Number of subjects: 23
Study 30630742 — intervention group
Group type: COMPARATOR
Intervention: CHO diet during Adapt trial
Number of subjects: 23
Study 30630742 — intervention group
Group type: EXPERIMENTAL
Intervention: LCHF diet during CHO Restoration trial
Number of subjects: 23
Study 30630742 — intervention group
Group type: COMPARATOR
Intervention: CHO diet during CHO Restoration trial
Number of subjects: 23
Study 30630742 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exercise hepcidin-25 concentrations
Number of subjects: 23
Study 29100250 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait retraining from rearfoot strike to forefoot strike (8 sessions)
Number of subjects: 16
Study 29100250 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16
Study 25458411 — intervention group
Group type: EXPERIMENTAL
Intervention: Phoenurse female condom (PFC)
Number of subjects: 290
Study 25458411 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation Femidom female condom (FC2)
Number of subjects: 290
Study 25458411 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PFC and FC2
Number of subjects: 290
Study 23400965 — intervention group
Group type: EXPERIMENTAL
Intervention: H₂-water (1,000 mL/day for 48 weeks)
Number of subjects: 17
Study 23400965 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pseudo water for 48 weeks)
Number of subjects: 17
Study 21512082 — intervention group
Group type: EXPERIMENTAL
Intervention: MR arthrography
Number of subjects: 42
Study 21512082 — intervention group
Group type: COMPARATOR
Intervention: Conventional MRI
Number of subjects: 42
Study 19999361 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinegar irrigation
Number of subjects: 40
Study 19999361 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antibiotics
Number of subjects: 40
Study 19999361 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 40
Study 16201678 — intervention group
Group type: EXPERIMENTAL
Intervention: Neotenous female partner (increased eye-size)
Number of subjects: 176
Study 16201678 — intervention group
Group type: COMPARATOR
Intervention: Mature female partner (decreased eye-size)
Number of subjects: 176
Study 10494638 — intervention group
Group type: EXPERIMENTAL
Intervention: Pouch reconstruction
Number of subjects: 49
Study 10494638 — intervention group
Group type: COMPARATOR
Intervention: Roux‐en‐Y reconstruction
Number of subjects: 49
Study 8640816 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (vitamin C 100 mg/day, vitamin E 280 mg/day, beta-carotene 25 mg/day) for 20 weeks
Number of subjects: 0
Study 8640816 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonsmokers without supplementation)
Number of subjects: 0
Study 1945724 — intervention group
Group type: EXPERIMENTAL
Intervention: Advertisement with a picture of prior earthquake damage
Number of subjects: 40
Study 1945724 — intervention group
Group type: COMPARATOR
Intervention: Advertisement without a picture of prior earthquake damage
Number of subjects: 40
Study 1945724 — intervention group
Group type: EXPERIMENTAL
Intervention: Advertisement with statistics on likelihood of an earthquake
Number of subjects: 40
Study 1945724 — intervention group
Group type: COMPARATOR
Intervention: Advertisement without statistics on likelihood of an earthquake
Number of subjects: 40
Study 6752720 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkylating agents (melphalan and chlorambucil)
Number of subjects: 1399
Study 6752720 — intervention group
Group type: COMPARATOR
Intervention: Surgery or radiation or both without alkylating agents
Number of subjects: 1399
Study 6752720 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone (alkylating agents)
Number of subjects: 1399
Study 30669181 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. fluid administration
Number of subjects: 0
Study 30669181 — intervention group
Group type: EXPERIMENTAL
Intervention: vasopressor use
Number of subjects: 0
Study 30669181 — intervention group
Group type: EXPERIMENTAL
Intervention: baseline demographics, clinical and laboratory variables
Number of subjects: 0
Study 30372711 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoximetasone spray 0.25% with twice-daily telephone calls to discuss treatment adherence
Number of subjects: 0
Study 30372711 — intervention group
Group type: COMPARATOR
Intervention: No treatment adherence support (control group)
Number of subjects: 0
Study 26827913 — intervention group
Group type: EXPERIMENTAL
Intervention: PSX1002-GB 12.5 μg
Number of subjects: 37
Study 26827913 — intervention group
Group type: EXPERIMENTAL
Intervention: PSX1002-GB 25 μg
Number of subjects: 37
Study 26827913 — intervention group
Group type: EXPERIMENTAL
Intervention: PSX1002-GB 50 μg
Number of subjects: 37
Study 26827913 — intervention group
Group type: EXPERIMENTAL
Intervention: PSX1002-GB 100 μg
Number of subjects: 37
Study 26827913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 24500245 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMe 1,600‐3,200 mg/d
Number of subjects: 189
Study 22866681 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 5992
Study 22866681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5992
Study 22866681 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 5992
Study 19683590 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 200microg
Number of subjects: 464
Study 19683590 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 400microg
Number of subjects: 464
Study 19683590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study 19683590 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium (all doses)
Number of subjects: 464
Study 19683590 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 100-400microg
Number of subjects: 464
Study 19683590 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium
Number of subjects: 464
Study 19683590 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18microg
Number of subjects: 464
Study 17686823 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor A (retinol and zinc)
Number of subjects: 29450
Study 17686823 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor B (riboflavin and niacin)
Number of subjects: 29450
Study 17686823 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor C (ascorbic acid and molybdenum)
Number of subjects: 29450
Study 17686823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29450
Study 17686823 — intervention group
Group type: EXPERIMENTAL
Intervention: Two factors (unspecified)
Number of subjects: 29450
Study 17686823 — intervention group
Group type: EXPERIMENTAL
Intervention: All four factors
Number of subjects: 29450
Study 15716198 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin (5 mg twice daily)
Number of subjects: 30
Study 15716198 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg once daily)
Number of subjects: 30
Study 15716198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11939919 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow rewarming strategy (0.24 degrees C/min)
Number of subjects: 50
Study 11939919 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast rewarming strategy (0.5 degrees C/min)
Number of subjects: 50
Study 11939919 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both rewarming strategies
Number of subjects: 50
Study 9791528 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Psychological Support (IPS)
Number of subjects: 527
Study 9791528 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 527
Study 7626351 — intervention group
Group type: COMPARATOR
Intervention: Warfarin treatment (group 2)
Number of subjects: 87
Study 7626351 — intervention group
Group type: EXPERIMENTAL
Intervention: No antithrombotic medication (group 1)
Number of subjects: 87
Study 7626351 — intervention group
Group type: COMPARATOR
Intervention: Aspirin treatment (group 3)
Number of subjects: 87
Study 2570535 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (20 micrograms/kg)
Number of subjects: 45
Study 2570535 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (4 micrograms/kg)
Number of subjects: 45
Study 30540617 — intervention group
Group type: EXPERIMENTAL
Intervention: LAI risperidone
Number of subjects: 5
Study 30540617 — intervention group
Group type: EXPERIMENTAL
Intervention: LAI SGAs
Number of subjects: 5
Study 25659140 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermistors
Number of subjects: 30
Study 25659140 — intervention group
Group type: EXPERIMENTAL
Intervention: iButtons
Number of subjects: 30
Study 25659140 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared thermometer
Number of subjects: 30
Study 25659140 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared camera
Number of subjects: 30
Study 25088865 — intervention group
Group type: EXPERIMENTAL
Intervention: Midurethral sling procedures (TOMUS and E-TOMUS)
Number of subjects: 597
Study 25088865 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant repair for symptomatic stage 2 POP at index sling surgery
Number of subjects: 597
Study 25088865 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic stage 2 POP
Number of subjects: 597